Press Release: Nodality, Inc. : Nodality Launches PathPro T Cell Receptor (TCR) and B Cell Receptor (BCR) Panels for Assessing Drug Impact on Functional Signaling in Primary Human Cells

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc. announced today the availability of its new PathPro T Cell Receptor (TCR) and B Cell Receptor (BCR) panels. These panels provide unique insights into disease and the impact of a compound or drug on BCR or TCR signaling in primary human cells. Each is designed to characterize cell signaling pathways at the single cell level for broad application in multiple therapeutic areas including autoimmune disease and cancer immunotherapy. Earli